EVP Van Naarden Jacob bought 1,000 LLY shares at $647.36; 6 other insiders bought within 14 days amid -31.2% decline from 52-week high.
Van Naarden Jacob, EVP & President of Lilly Oncology, purchased 1,000 shares at $647.36, increasing his holdings from 19,561 to 20,561 shares (+5.1%). The transaction occurs as LLY stock has declined 31.2% from its 52-week high of $960.02 and fallen 17.4% over the prior 30 days, creating a notably depressed price environment relative to recent history. More significantly, this buy is part of a cluster pattern: 6 other insiders also purchased shares within the past 14 days, suggesting coordinated or coincident confidence at a depressed valuation level. The company's fundamentals remain strong with $15.6B in quarterly revenue, $5.7B net income, and 32.0% annual revenue growth, providing context for insider accumulation during a sharp drawdown.